Results 141 to 150 of about 12,160,166 (292)
We identified a systemic, progressive loss of protein S‐glutathionylation—detected by nonreducing western blotting—alongside dysregulation of glutathione‐cycle enzymes in both neuronal and peripheral tissues of Taiwanese SMA mice. These alterations were partially rescued by SMN antisense oligonucleotide therapy, revealing persistent redox imbalance as ...
Sofia Vrettou, Brunhilde Wirth
wiley +1 more source
Climate change: north and south EU economies-an application of dynamic asymmetric panel data models. [PDF]
Adam C, Drakos P.
europepmc +1 more source
β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1
Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero +8 more
wiley +1 more source
Common data models and data standards for tabular health data: a systematic review. [PDF]
Finster M, Wenzel M, Taghizadeh E.
europepmc +1 more source
Empirical likelihood for spatial dynamic panel data models. [PDF]
Li Y, Qin Y.
europepmc +1 more source
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou +5 more
wiley +1 more source
Confidence, animal spirits, and the macroeconomy in China: Based on mixed-frequency data models. [PDF]
Lu W, Liu Q, Li H.
europepmc +1 more source
Piloting an automated clinical trial eligibility surveillance and provider alert system based on artificial intelligence and standard data models. [PDF]
Meystre SM +6 more
europepmc +1 more source
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham +21 more
wiley +1 more source
Data models, representation and adequacy-for-purpose. [PDF]
Bokulich A, Parker W.
europepmc +1 more source

